Table 2.
Demographic and Ocular Characteristics at Baseline and the Final Visit in the Follow-Up Group
| Characteristics | Pachychoroid GA |
Conventional GA |
P value∗ |
|||
|---|---|---|---|---|---|---|
| Baseline | Final | Baseline | Final | Baseline | Final | |
| Patients, n | 22 | 79 | ||||
| Follow-up period (median, range), month | 57.0 ± 32.4 (56.5, 6–123) | 43.2 ± 27.2 (38.0, 6–110) | 0.078 | |||
| Age (median, range), years | 71.2 ± 8.7 (70.5, 56–86) | 76.1 ± 7.6 (76, 63–90) | 78.1 ± 8.2 (79, 53–94) | 81.7 ± 7.9 (83, 58–95) | 0.002 | 0.002 |
| Sex, n, males (%) | 20 (90.9) | 43 (54.4) | 0.002 | |||
| Smoking status, n, current or former (%); n = 90 | 16 (84.2) | 34 (47.9) | 0.005 | |||
| Axial length (median), mm; n = 80 | 23.4 ± 1.0 (23.3) | 23.5 ± 0.9 (23.6) | 0.447 | |||
| BCVA, logMAR (Snellen equivalent) | 0.19 ± 0.30 (20/31) | 0.26 ± 0.31 (20/36) | 0.39 ± 0.46 (20/49) | 0.55 ± 0.53 (20/71) | 0.086 | 0.026 |
| CMT (median, range), μm | 146.5 ± 60.2 (152.5, 17.0–224.0) | 121.1 ± 74.2 (146, 9.0–227.0) | 148.5 ± 84.8 (151, 6.0–617.0) | 116.5 ± 71.4 (105, 6.0–285.0) | 0.072† | 0.021† |
| SFCT (median, range), μm | 325.0 ± 125.2 (324, 140.5–622.0) | 287.7 ± 109.7 (292, 110.5–571.0) | 164.4 ± 78.5 (155, 36.5–414.0) | 150.1 ± 77.5 (143, 15.5–414.0) | <0.001‡ | <0.001‡ |
| CMT thinning (median, range), μm/year | 4.7 ± 8.2 (2.6, −8.0 to 21.8) | 13.6 ± 27.6 (5.1, −12.5 to 162.4) | 0.097 | |||
| SFCT thinning (median, range), μm/year | 6.5 ± 16.1 (5.4, −50.4 to 32.0) | 4.1 ± 15.3 (3.4, −62 to 58.2) | 0.093 | |||
| GA area (median, range), mm2 | 0.65 ± 0.88 (0.26, 0.07–2.81) | 1.91 ± 2.05 (1.10, 0.15–6.75) | 3.36 ± 3.61 (2.29, 0.05–16.16) | 7.24 ± 7.15 (5.47, 0.16–37.10) | <0.001 | <0.001 |
| GA area [SQRT] (median, range), mm | 0.68 ± 0.44 (0.50, 0.26–1.68) | 1.20 ± 0.70 (1.05, 0.38–2.60) | 1.56 ± 0.96 (1.51, 0.23–4.02) | 2.38 ± 1.26 (2.34, 0.40–6.09) | <0.001 | <0.001 |
| GA progression rate (median, range), mm2/year | 0.23 ± 0.25 (0.12, 0.02–1.08) | 1.22 ± 1.13 (0.81, 0.02–4.59) | <0.001 | |||
| GA progression rate [SQRT] (median, range), mm/year | 0.11 ± 0.07 (0.09, 0.02–0.34) | 0.27 ± 0.18 (0.25, 0.01–0.70) | <0.001 | |||
| GA location, central/non-central | 8/14 | 11/11 | 43/36 | 55/24 | 0.154 | 0.127 |
| GA type, unifocal/multifocal | 21/1 | 21/1 | 42/37 | 38/41 | <0.001 | <0.001 |
| Drusen, n, present (%) | 0 (0) | 67 (84.8) | <0.001 | |||
| Reticular pseudodrusen, n, present (%) | 0 (0) | 43 (54.4) | <0.001 | |||
| MNV development, n§ | 1 | 5 | 1.000 | |||
| Fellow eye status, GA/neovascular AMD/intermediate AMD/no AMD; n = 100‖ | 1/6/0/15 | 3/6/0/13 | 30/31/15/2 | 34/33/9/2 | <0.001 | <0.001 |
AMD = age-related macular degeneration; BCVA = best-corrected visual acuity; CMT = central macular thickness; GA = geographic atrophy; logMAR = logarithm of the minimum angle of resolution; MNV = macular neovascularization; n = number of patients; SFCT = subfoveal choroidal thickness; SQRT = square-root transformation.
∗
Pachychoroid GA vs conventional GA.
†
Age-adjusted.
‡
Age and sex-adjusted.
§
The subsequent period was not included in the follow-up analysis when macular neovascularization developed during the course of the disease.
‖
In 1 patient, information on the fellow eye was lacking due to phthisis.